Can Vitamin D3 Improve Cognitive Function in Individuals With Type 2 Diabetes? (THINK-D)

NCT ID: NCT02416193

Last Updated: 2020-10-23

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 56 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-09-23
• Study Completion Date: 2018-07-12

Brief Summary

Diabetes increases the risk of cognitive dysfunction. The incidence of dementia is 1.5 to 2.5 times higher in persons with diabetes than the general population. There is evidence that cognitive decline significantly impacts the ability to self-manage diabetes. Strategies to prevent cognitive decline in persons with diabetes has not been well studied. A recent study reported that in persons who had vitamin D deficiency, the risk for all-cause dementia and Alzheimer's was doubled. Vitamin D receptors are located in the brain and deficiency of vitamin D has been reported to negatively affect the development of brain. Therefore, providing vitamin D supplementation to improve cognitive function is worthy of study. The investigators propose a small, randomized controlled trial to determine the effects of vitamin D3 supplementation in persons with type 2 diabetes who have symptoms of cognitive impairment. Persons will be randomized to receive either weekly vitamin D3 supplementation (50,000 IUs) or a matching comparator (5000 IUs) for a period of three months. The study aims are to determine (1) the effect of vitamin D3 supplementation on cognitive function and (2) the effect of vitamin D3 supplementation on diabetes self-management. A sample of persons with type 2 diabetes (n=62), who have a subjective complaint of a cognitive dysfunction or scoring at least one standard deviation below normal on a cognitive functioning screening test, have vitamin D levels less 30 ng/ml, are not depressed (as this impacts cognitive function), and do not have severe diabetes complication will be recruited. Participants will be phone screened and complete two baseline visits prior to randomization. They will then have phone call and follow-up visits to assess (1) cognitive function using standardized tests to assess for executive function (2) serum measurements (HBA1c, fasting glucose, vitamin D levels, and cardiometabolic profile) and (3) surveys to assess cognitive function as well as self-management behaviors.

Detailed Description

Study Aims Diabetes increases the risk of cognitive dysfunction. The incidence of dementia is 1.5 to 2.5 times higher in persons with diabetes than the general population (1). There is evidence that cognitive decline significantly impacts the ability to self-manage diabetes (2). Strategies to prevent cognitive decline in persons with diabetes has not been well studied. A recent study reported that in persons who had vitamin D deficiency, the risk for all-cause dementia and Alzheimer's was doubled (3). Vitamin D receptors are located in the brain, and deficiency of vitamin D has been reported to negatively affect the development of brain and impact both growth factor signaling and neural activity (4, 5). Therefore, providing vitamin D supplementation to improve cognitive function in persons with diabetes who are at great risk for this comorbid condition is important. The investigators propose a small, randomized controlled trial to determine the effects of vitamin D3 supplementation in persons with type 2 diabetes who have symptoms of cognitive impairment. Persons will be randomized to receive either weekly vitamin D3 supplementation (50,000 IUs) or a matching comparator (5000 IUs) for a period of three months.

Primary Aim: To determine the effect of vitamin D3 supplementation on cognitive function for persons with type 2 diabetes.

Primary Hypothesis: Persons receiving weekly vitamin D3 supplementation (50,000 IUs) will have improved cognitive function compared to those receiving the comparator (5000 IUs) at three months.

Secondary Aim: To determine the effect of vitamin D3 supplementation on diabetes self-management.

Secondary Hypothesis: Persons receiving weekly vitamin D3 supplementation (50,000 IUs) will have improved self-management compared to those receiving the comparator (5000 IUs) at three months.

The importance of this study is several fold. Vitamin D supplementation is a low cost intervention (6), it has minimal side effects (7), and it could have high impact for persons with type 2 diabetes who suffer from cognitive impairment which can significantly affect their diabetes self-management.

Conditions

Diabetes; Executive Dysfunction

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

High Dose

50,000 IU cholecalciferol once weekly for three months

Group Type: EXPERIMENTAL

Cholecalciferol

Intervention Type: DRUG

Participants will take randomly assigned high dose cholecalciferol once weekly for three months

Low Dose

5,000 IU cholecalciferol once weekly for three months

Group Type: ACTIVE_COMPARATOR

Cholecalciferol

Intervention Type: DRUG

Participants will take randomly assigned active comparator cholecalciferol once weekly for three months

Interventions

Cholecalciferol

Participants will take randomly assigned high dose cholecalciferol once weekly for three months

Intervention Type: DRUG

Cholecalciferol

Participants will take randomly assigned active comparator cholecalciferol once weekly for three months

Intervention Type: DRUG

Other Intervention Names

Vitamin D3; Vitamin D3

Eligibility Criteria

Inclusion Criteria

• Women and men aged 18 to 75 years
• Have type 2 diabetes
• Having a subjective complaint of a cognitive dysfunction or scoring at least one standard deviation below normal on a cognitive functioning screening test
• Vitamin D level as measured by 25-hydroxyvitamin D (25-OH D) < 32 ng/mL
• Under the care of a healthcare provider
• Systolic blood pressure ≤160 and diastolic blood pressure ≤100

Exclusion Criteria

• Persons with malabsorption problems (e.g., crohn's disease)
• Hypercalcemia
• Supplementation other than a daily multivitamin
• Severe complications of diabetes (i.e., amputation, blindness, and dialysis)
• Concomitant use of steroids
• GFR < 60
• Creatinine > 1.2
• Significant depressive symptoms
• Having a history of bipolar depression, psychotic disorders, loss of consciousness greater than 5 minutes, or a current alcohol or substance use disorder
• Other serious medical conditions deemed significant by the PI or medical monitor
• Concomitant use of cholinesterase inhibitors
• Concomitant use of anxiolytics, kava kava, St. John's Wort, or Ginkgo Biloba
• Pregnancy
• HbA1c >13%

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Chicago

OTHER

Sponsor Role: collaborator

Loyola University

OTHER

Sponsor Role: lead

Responsible Party

Mary A Byrn

Assistant Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Mary A Byrn, Ph.D., R.N.

Role: PRINCIPAL_INVESTIGATOR

Loyola University

Locations

Loyola University Medical Center

Maywood, Illinois, United States

Countries

United States

References

Lee JH, Choi Y, Jun C, Hong YS, Cho HB, Kim JE, Lyoo IK. Neurocognitive changes and their neural correlates in patients with type 2 diabetes mellitus. Endocrinol Metab (Seoul). 2014 Jun;29(2):112-21. doi: 10.3803/EnM.2014.29.2.112.

Reference Type: BACKGROUND

PMID: 25031883 (View on PubMed)

Smith MA, Else JE, Paul L, Foster JK, Walker M, Wesnes KA, Riby LM. Functional Living in Older Adults With Type 2 Diabetes: Executive Functioning, Dual Task Performance, and the Impact on Postural Stability and Motor Control. J Aging Health. 2014 Aug;26(5):841-859. doi: 10.1177/0898264314534896. Epub 2014 Jun 4.

Reference Type: BACKGROUND

PMID: 24898849 (View on PubMed)

Littlejohns TJ, Henley WE, Lang IA, Annweiler C, Beauchet O, Chaves PH, Fried L, Kestenbaum BR, Kuller LH, Langa KM, Lopez OL, Kos K, Soni M, Llewellyn DJ. Vitamin D and the risk of dementia and Alzheimer disease. Neurology. 2014 Sep 2;83(10):920-8. doi: 10.1212/WNL.0000000000000755. Epub 2014 Aug 6.

Reference Type: BACKGROUND

PMID: 25098535 (View on PubMed)

McCann JC, Ames BN. Is there convincing biological or behavioral evidence linking vitamin D deficiency to brain dysfunction? FASEB J. 2008 Apr;22(4):982-1001. doi: 10.1096/fj.07-9326rev. Epub 2007 Dec 4.

Reference Type: BACKGROUND

PMID: 18056830 (View on PubMed)

Schlogl M, Holick MF. Vitamin D and neurocognitive function. Clin Interv Aging. 2014 Apr 2;9:559-68. doi: 10.2147/CIA.S51785. eCollection 2014.

Reference Type: BACKGROUND

PMID: 24729696 (View on PubMed)

Holick MF. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc. 2006 Mar;81(3):353-73. doi: 10.4065/81.3.353.

Reference Type: BACKGROUND

PMID: 16529140 (View on PubMed)

Holick MF. Vitamin D deficiency. N Engl J Med. 2007 Jul 19;357(3):266-81. doi: 10.1056/NEJMra070553. No abstract available.

Reference Type: BACKGROUND

PMID: 17634462 (View on PubMed)

Tuligenga RH, Dugravot A, Tabak AG, Elbaz A, Brunner EJ, Kivimaki M, Singh-Manoux A. Midlife type 2 diabetes and poor glycaemic control as risk factors for cognitive decline in early old age: a post-hoc analysis of the Whitehall II cohort study. Lancet Diabetes Endocrinol. 2014 Mar;2(3):228-35. doi: 10.1016/S2213-8587(13)70192-X. Epub 2013 Dec 19.

Reference Type: BACKGROUND

PMID: 24622753 (View on PubMed)

Wennberg AMV, Gottesman RF, Kaufmann CN, Albert MS, Chen-Edinboro LP, Rebok GW, Kasper JD, Spira AP. Diabetes and cognitive outcomes in a nationally representative sample: the National Health and Aging Trends Study. Int Psychogeriatr. 2014 Oct;26(10):1729-1735. doi: 10.1017/S1041610214001380. Epub 2014 Jul 30.

Reference Type: BACKGROUND

PMID: 25075535 (View on PubMed)

Munshi MN, Hayes M, Iwata I, Lee Y, Weinger K. Which aspects of executive dysfunction influence ability to manage diabetes in older adults? Diabet Med. 2012 Sep;29(9):1171-7. doi: 10.1111/j.1464-5491.2012.03606.x.

Reference Type: BACKGROUND

PMID: 22340082 (View on PubMed)

Grober E, Hall CB, Hahn SR, Lipton RB. Memory Impairment and Executive Dysfunction are Associated with Inadequately Controlled Diabetes in Older Adults. J Prim Care Community Health. 2011 Oct 1;2(4):229-33. doi: 10.1177/2150131911409945. Epub 2011 Jun 1.

Reference Type: BACKGROUND

PMID: 23804840 (View on PubMed)

Retracted: Executive dysfunction in elderly diabetic patients. Geriatr Gerontol Int. 2015 Aug;15(8):1106. doi: 10.1111/ggi.12288. Epub 2014 Apr 21. No abstract available.

Reference Type: BACKGROUND

PMID: 24750335 (View on PubMed)

Winkler A, Dlugaj M, Weimar C, Jockel KH, Erbel R, Dragano N, Moebus S. Association of diabetes mellitus and mild cognitive impairment in middle-aged men and women. J Alzheimers Dis. 2014;42(4):1269-77. doi: 10.3233/JAD-140696.

Reference Type: BACKGROUND

PMID: 25024326 (View on PubMed)

Geijselaers SLC, Sep SJS, Stehouwer CDA, Biessels GJ. Glucose regulation, cognition, and brain MRI in type 2 diabetes: a systematic review. Lancet Diabetes Endocrinol. 2015 Jan;3(1):75-89. doi: 10.1016/S2213-8587(14)70148-2. Epub 2014 Aug 24.

Reference Type: BACKGROUND

PMID: 25163604 (View on PubMed)

Annweiler C, Montero-Odasso M, Llewellyn DJ, Richard-Devantoy S, Duque G, Beauchet O. Meta-analysis of memory and executive dysfunctions in relation to vitamin D. J Alzheimers Dis. 2013;37(1):147-71. doi: 10.3233/JAD-130452.

Reference Type: BACKGROUND

PMID: 23948884 (View on PubMed)

Penckofer S, Kouba J, Wallis DE, Emanuele MA. Vitamin D and diabetes: let the sunshine in. Diabetes Educ. 2008 Nov-Dec;34(6):939-40, 942, 944 passim. doi: 10.1177/0145721708326764.

Reference Type: BACKGROUND

PMID: 19075078 (View on PubMed)

Gulseth HL, Gjelstad IM, Tierney AC, Lovegrove JA, Defoort C, Blaak EE, Lopez-Miranda J, Kiec-Wilk B, Riserus U, Roche HM, Drevon CA, Birkeland KI. Serum vitamin D concentration does not predict insulin action or secretion in European subjects with the metabolic syndrome. Diabetes Care. 2010 Apr;33(4):923-5. doi: 10.2337/dc09-1692. Epub 2010 Jan 12.

Reference Type: BACKGROUND

PMID: 20067973 (View on PubMed)

Davidson MB, Duran P, Lee ML, Friedman TC. High-dose vitamin D supplementation in people with prediabetes and hypovitaminosis D. Diabetes Care. 2013 Feb;36(2):260-6. doi: 10.2337/dc12-1204. Epub 2012 Oct 1.

Reference Type: BACKGROUND

PMID: 23033239 (View on PubMed)

Penckofer S, Kouba J, Byrn M, Estwing Ferrans C. Vitamin D and depression: where is all the sunshine? Issues Ment Health Nurs. 2010 Jun;31(6):385-93. doi: 10.3109/01612840903437657.

Reference Type: BACKGROUND

PMID: 20450340 (View on PubMed)

Drechsler C, Schmiedeke B, Niemann M, Schmiedeke D, Kramer J, Turkin I, Blouin K, Emmert A, Pilz S, Obermayer-Pietsch B, Weidemann F, Breunig F, Wanner C. Potential role of vitamin D deficiency on Fabry cardiomyopathy. J Inherit Metab Dis. 2014 Mar;37(2):289-95. doi: 10.1007/s10545-013-9653-8. Epub 2013 Oct 19.

Reference Type: BACKGROUND

PMID: 24141790 (View on PubMed)

Alves MR, Yamamoto T, Arias-Carrion O, Rocha NB, Nardi AE, Machado S, Silva AC. Executive function impairments in patients with depression. CNS Neurol Disord Drug Targets. 2014;13(6):1026-40. doi: 10.2174/1871527313666140612102321.

Reference Type: BACKGROUND

PMID: 24923347 (View on PubMed)

Zahodne LB, Nowinski CJ, Gershon RC, Manly JJ. Depressive symptoms are more strongly related to executive functioning and episodic memory among African American compared with non-Hispanic White older adults. Arch Clin Neuropsychol. 2014 Nov;29(7):663-9. doi: 10.1093/arclin/acu045. Epub 2014 Oct 3.

Reference Type: BACKGROUND

PMID: 25280795 (View on PubMed)

Jorde R, Sneve M, Figenschau Y, Svartberg J, Waterloo K. Effects of vitamin D supplementation on symptoms of depression in overweight and obese subjects: randomized double blind trial. J Intern Med. 2008 Dec;264(6):599-609. doi: 10.1111/j.1365-2796.2008.02008.x. Epub 2008 Sep 10.

Reference Type: BACKGROUND

PMID: 18793245 (View on PubMed)

Burton JM, Kimball S, Vieth R, Bar-Or A, Dosch HM, Cheung R, Gagne D, D'Souza C, Ursell M, O'Connor P. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology. 2010 Jun 8;74(23):1852-9. doi: 10.1212/WNL.0b013e3181e1cec2. Epub 2010 Apr 28.

Reference Type: BACKGROUND

PMID: 20427749 (View on PubMed)

Nazarian S, St Peter JV, Boston RC, Jones SA, Mariash CN. Vitamin D3 supplementation improves insulin sensitivity in subjects with impaired fasting glucose. Transl Res. 2011 Nov;158(5):276-81. doi: 10.1016/j.trsl.2011.05.002. Epub 2011 Jun 7.

Reference Type: BACKGROUND

PMID: 22005267 (View on PubMed)

Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc. 2005 Jul;80(7):856-61. doi: 10.4065/80.7.856.

Reference Type: BACKGROUND

PMID: 16007889 (View on PubMed)

Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM; Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011 Jul;96(7):1911-30. doi: 10.1210/jc.2011-0385. Epub 2011 Jun 6.

Reference Type: BACKGROUND

PMID: 21646368 (View on PubMed)

Mitri J, Dawson-Hughes B, Hu FB, Pittas AG. Effects of vitamin D and calcium supplementation on pancreatic beta cell function, insulin sensitivity, and glycemia in adults at high risk of diabetes: the Calcium and Vitamin D for Diabetes Mellitus (CaDDM) randomized controlled trial. Am J Clin Nutr. 2011 Aug;94(2):486-94. doi: 10.3945/ajcn.111.011684. Epub 2011 Jun 29.

Reference Type: BACKGROUND

PMID: 21715514 (View on PubMed)

Koutkia P, Lu Z, Chen TC, Holick MF. Treatment of vitamin D deficiency due to Crohn's disease with tanning bed ultraviolet B radiation. Gastroenterology. 2001 Dec;121(6):1485-8. doi: 10.1053/gast.2001.29686.

Reference Type: BACKGROUND

PMID: 11729127 (View on PubMed)

Lips P. Which circulating level of 25-hydroxyvitamin D is appropriate? J Steroid Biochem Mol Biol. 2004 May;89-90(1-5):611-4. doi: 10.1016/j.jsbmb.2004.03.040.

Reference Type: BACKGROUND

PMID: 15225848 (View on PubMed)

Etgen T, Sander D, Bickel H, Sander K, Forstl H. Vitamin D deficiency, cognitive impairment and dementia: a systematic review and meta-analysis. Dement Geriatr Cogn Disord. 2012;33(5):297-305. doi: 10.1159/000339702. Epub 2012 Jul 2.

Reference Type: BACKGROUND

PMID: 22759681 (View on PubMed)

Wallis DE, Penckofer S, Sizemore GW. The "sunshine deficit" and cardiovascular disease. Circulation. 2008 Sep 30;118(14):1476-85. doi: 10.1161/CIRCULATIONAHA.107.713339. No abstract available.

Reference Type: BACKGROUND

PMID: 18824654 (View on PubMed)

Glanz K, Yaroch AL, Dancel M, Saraiya M, Crane LA, Buller DB, Manne S, O'Riordan DL, Heckman CJ, Hay J, Robinson JK. Measures of sun exposure and sun protection practices for behavioral and epidemiologic research. Arch Dermatol. 2008 Feb;144(2):217-22. doi: 10.1001/archdermatol.2007.46.

Reference Type: BACKGROUND

PMID: 18283179 (View on PubMed)

Cummings SR, Block G, McHenry K, Baron RB. Evaluation of two food frequency methods of measuring dietary calcium intake. Am J Epidemiol. 1987 Nov;126(5):796-802. doi: 10.1093/oxfordjournals.aje.a114716.

Reference Type: BACKGROUND

PMID: 3661527 (View on PubMed)

Welch G, Weinger K, Anderson B, Polonsky WH. Responsiveness of the Problem Areas In Diabetes (PAID) questionnaire. Diabet Med. 2003 Jan;20(1):69-72. doi: 10.1046/j.1464-5491.2003.00832.x.

Reference Type: BACKGROUND

PMID: 12519323 (View on PubMed)

Ruff RM, Light RH, Parker SB, Levin HS. Benton Controlled Oral Word Association Test: reliability and updated norms. Arch Clin Neuropsychol. 1996;11(4):329-38.

Reference Type: BACKGROUND

PMID: 14588937 (View on PubMed)

Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989 May;28(2):193-213. doi: 10.1016/0165-1781(89)90047-4.

Reference Type: BACKGROUND

PMID: 2748771 (View on PubMed)

Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav. 1983 Dec;24(4):385-96. No abstract available.

Reference Type: BACKGROUND

PMID: 6668417 (View on PubMed)

Gameroff MJ, Wickramaratne P, Weissman MM. Testing the Short and Screener versions of the Social Adjustment Scale-Self-report (SAS-SR). Int J Methods Psychiatr Res. 2012 Mar;21(1):52-65. doi: 10.1002/mpr.358. Epub 2011 Dec 5.

Reference Type: BACKGROUND

PMID: 22139969 (View on PubMed)

Endicott J, Nee J. Endicott Work Productivity Scale (EWPS): a new measure to assess treatment effects. Psychopharmacol Bull. 1997;33(1):13-6.

Reference Type: BACKGROUND

PMID: 9133746 (View on PubMed)

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Document Type: Informed Consent Form

View Document

Other Identifiers

206988031815

Identifier Type: OTHER

Identifier Source: secondary_id

206988

Identifier Type: -

Identifier Source: org_study_id